TCB Team is a group of domain experts and writers focused on biotech, healthcare, and AI. They deliver original, high-signal coverage tailored for industry professionals, investors, and researchers. With a neutral and independent voice, the team transforms complex developments into clear, actionable insights.
110 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biotech InnovationThe biotech company’s innovative RNAi-based therapies showed encouraging outcomes in early clinical trials targeting obesity, highlighting gene-silencing technology’s expanding role in metabolic diseases.
TCB TeamJan 6, 2026
Medical TechnologyThe FDA aims to encourage innovation and deployment of AI-enabled medical devices by reducing oversight, signaling a shift in regulatory approach toward digital health technology.
TCB TeamJan 6, 2026
Medical TechnologyWith the rise of telehealth services, providers are leveraging digital platforms to deliver the popular Wegovy pill, reflecting digital health’s role in expanding obesity treatment access.
TCB TeamJan 6, 2026
Biotech InnovationArrowhead Pharmaceuticals reported that its gene-silencing candidates were successful in helping people with obesity lose fat, marking an advancement in RNA medicine aimed at managing obesity.
TCB TeamJan 6, 2026
Medical TechnologyThe launch of the oral Wegovy pill has triggered a swift response from telehealth platforms aiming to capitalize on the growing obesity treatment market by expanding access to this convenient medication deployment option.
TCB TeamJan 6, 2026
Regulatory & PolicyIn a recent regulatory update, the FDA declined approval of Sanofi’s tolebrutinib for a specific form of multiple sclerosis, citing concerns relating to toxicities and ambiguous clinical efficacy. This decision presents a significant hurdle for the therapy's development.
TCB TeamJan 6, 2026
Healthcare InvestmentAn announcement from investment firm Catalio highlights its strategic commitment to autoimmune disease innovation through leadership appointment at a newly formed biotech startup dedicated to this area.
TCB TeamJan 6, 2026
Regulatory & PolicyThe number of recommended childhood vaccinations has been significantly trimmed, raising concerns among health experts about the new vaccine schedule's impact on children's near- and long-term health. This major policy change alters the longstanding immunization framework.
TCB TeamJan 6, 2026
Regulatory & PolicyIn an effort to encourage innovation and adoption of digital health products, the FDA will reduce regulatory burdens on wearables and AI-powered devices, marking a strategic departure from past stringent oversight.
TCB TeamJan 6, 2026
Healthcare InvestmentAs healthcare systems become increasingly strained, emphasis on personalized patient experiences and empathy is growing. Investment and innovation focused on scaling these human-centered approaches may redefine patient satisfaction and competitive positioning.
TCB TeamJan 6, 2026
Regulatory & PolicySanofi's experimental oral BTK inhibitor tolebrutinib, intended for multiple sclerosis treatment, hit a regulatory setback with the FDA last month. The agency's detailed refusal highlights ongoing challenges in balancing drug safety and therapeutic proof in neuroimmune diseases.
TCB TeamJan 6, 2026
Regulatory & PolicyDespite repeated extensions of telehealth prescribing flexibilities by the DEA and other agencies, uncertainty remains. The AMA advocates for permanent legislative action to ensure stable patient access and provider reimbursement for telehealth services.
TCB TeamJan 6, 2026